# US 2022/0017980 A1 · Compositions and methods for amplifying or detecting varicella-zoster virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017980 A1
- Document ID: US20220017980A1
- Status: Published application
- Kind: A1
- Application number: 17/281,543
- Filed: 2019-10-01
- Published: 2022-01-20
- Earliest claimed: 2018-10-01
- Assignees: Gen-Probe Incorporated
- Applicants: Gen-Probe Incorporated
- Inventors: Marcela Alejandra CARVALLO PINTO; Amber Jean HILLIUS; Ankur SHAH
- Web page: https://patentgrep.com/patent/US20220017980A1

## CPC

- C12Q 1/6888: for detection or identification of organisms
- C12Q 1/705: {for herpetoviridae, e.g. herpes simplex, varicella zoster}
- C12Q 1/701: {Specific hybridization probes}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed are oligonucleotides, oligonucleotide compositions, kits, methods, formulations, and reaction mixtures that provide for sensitive and specific detection of a target nucleic acid sequence, or amplicon generated from a target nucleic acid sequence, of Varicella-Zoster Virus (VZV1 (if present) in a sample. The oligonucleotides, compositions, kits, methods, formulations, and reaction mixtures can be used to detect the presence of VZV in a sample. The oligonucleotides, compositions, kits, methods, formulations, and reaction mixtures can also be used to amplify specific target nucleic acid regions of VZV.

## Claims

### Claim 1

A composition for amplifying a Varicella-Zoster Virus (VZV) target nucleic acid sequence comprising: (a) a forward amplification primer 19-50 nucleobase in length comprising 19-23 contiguous nucleobases having at least 90% identity to a 19-23 nucleotide sequence present in SEQ ID NO:38 or a complement thereof or SEQ ID NO:39 or a complement thereof; and (b) a reverse amplification primer 19-50 nucleobase in length comprising 19-23 contiguous nucleobases having at least 90% identity to a 19-23 nucleotide sequence present in SEQ ID NO:38 or a complement thereof or SEQ ID NO:39 or a complement thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 23, 24, 25, 26, or 27.

### Claim 3 (depends on 1, 2)

The composition of any one of claims 1-2, wherein the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:16, 17, 18, 19, 20, 21, 22, 34, 35, 36 or 37.

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1-3, wherein:
(a) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:1 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:16;
(b) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:1 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:17;
(c) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:2 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:17;
(d) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:3 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:18;
(e) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:4 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:19;
(f) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:5 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:20;
(g) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:6 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:21;
(h) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:7 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:22;
(i) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:23 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:34;
(j) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:24 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:34;
(k) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:25 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:35;
(l) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:26 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:36; or
(m) the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:27 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:37.

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1-4, further comprising a detection probe for detecting an amplified Varicella-Zoster Virus (VZV) target nucleic acid sequence, wherein the detection probe comprises at least one detectable label.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the detection probe comprises the nucleobase sequence of SEQ ID NO:8, 9, 10, 11, 12, 13, 14, 15, 28, 29, 30, 31, 32, or 33.

### Claim 7 (depends on 6)

The composition of claim 6 wherein:
(a) the detection probe comprises the nucleobase sequence of SEQ ID NO:8 or 9, the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:1, and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO: 16 or 17;
(b) the detection probe comprises the nucleobase sequence of SEQ ID NO:9, the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:2 and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:17;
(c) the detection probe comprises the nucleobase sequence of SEQ ID NO:10, the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:3, and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:18;
(d) the detection probe comprises the nucleobase sequence of SEQ ID NO:11 or 12, the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:4, and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:19;
(f) the detection probe comprises the nucleobase sequence of SEQ ID NO:13 the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:5, and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:20;
(g) the detection probe comprises the nucleobase sequence of SEQ ID NO:14 the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:6, and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:21;
(h) the detection probe comprises the nucleobase sequence of SEQ ID NO:15 the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:7, and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:22;
(i) the detection probe comprises the nucleobase sequence of SEQ ID NO:28 the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:23 or 24, and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:34;
(j) the detection probe comprises the nucleobase sequence of SEQ ID NO:29 or 30, the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:25, and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:35;
(k) the detection probe comprises the nucleobase sequence of SEQ ID NO:31, the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:26, and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:36; or
(l) the detection probe comprises the nucleobase sequence of SEQ ID NO:32 or 33, the forward amplification primer comprises the nucleobase sequence of SEQ ID NO:27, and the reverse amplification primer comprises the nucleobase sequence of SEQ ID NO:37.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of any one of claims 1-7, wherein the forward amplification primer, the reverse amplification primer, and/or the detection probe comprises at least one modified nucleotide.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the modified nucleotide comprises: a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, or a 5-methylcytosine.

### Claim 10 (depends on 5, 6, 7, 8, 9)

The composition of any one of claims 5-9, wherein the at least one detectable label is selected from the group consisting of:
(a) a chemiluminescent label;
(b) a fluorescent label;
(c) a quencher; or
(d) a combination of two or more of (a), (b), and (c).

### Claim 11 (depends on 10)

The composition of claim 10, wherein the at least one detectable label comprises the fluorescent label, the quencher; or both the fluorescent label and the quencher.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11, wherein the detection probe comprises a 5′ non-target-hybridizing sequence base pairs with the 3′ end of the detection probe or the 3′ non-target-hybridizing sequence base pairs with the 5′ end of the detection probe.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the detection probe comprises a molecular beacon or a molecular torch.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1-13, further comprising one or more of: buffer, salt, dNTPs, detergent, and enzyme.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the enzyme comprises: a thermostable DNA polymerase, a reverse transcriptase, an RNA polymerase, or a combination of any two or more of a thermostable DNA polymerase, a reverse transcriptase, and an RNA polymerase.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The composition of any one of claims 1-15, wherein the amplification primers are in aqueous solution, frozen, or lyophilized.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The composition of any one of claims 1-16, wherein the composition comprises two or more pairs of amplification primers and/or two or more detection probes, wherein each pair of amplification primers consists of a forward amplification primer and a reverse amplification primer.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the two or more pairs of amplification primers and/or two or more detection probes amplify target nucleic acid sequences in the same or different organisms.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The composition of any of one of claims 1-18, further comprising an internal control target nucleic acid sequence, oligomers for amplifying and/or detecting an internal control target nucleic acid sequence, or a combination thereof.

### Claim 20

A detection probe for detecting a VZV target nucleic acid sequence comprising: an oligonucleotide comprising the nucleobase sequence of SEQ ID NO: 8, 9, 10, 11, 12, 13, 14, 15, 28, 29, 30, 31, 32, or 33, wherein the oligonucleotide contains one or more detectable labels.

### Claim 21 (depends on 20)

The detection probe of claim 20, wherein the detection probe comprises at least one modified nucleotide.

### Claim 22 (depends on 21)

The detection probe of claim 21, wherein the modified nucleotide comprises: a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, or a 5-methylcytosine.

### Claim 23 (depends on 20, 21, 22)

The detection probe of any one of claims 20-22, wherein one or more of the detectable labels is selected from the group consisting of:
(a) a chemiluminescent label;
(b) a fluorescent label;
(c) a quencher; or
(d) a combination of two or more of (a), (b), and (c).

### Claim 24 (depends on 23)

The detection probe of claim 23, wherein one or more of the detectable labels comprises the fluorescent label, the quencher; or both the fluorescent label and the quencher.

### Claim 25 (depends on 20, 21, 22, 23, 24)

The detection probe of any one of claims 20-24, wherein the detection probe comprises a 5′ non-target-hybridizing sequence that base pairs with the 3′ end of the detection probe or a 3′ non-target-hybridizing sequence that base pairs with the 5′ end of the detection probe.

### Claim 26 (depends on 25)

The detection probe of claim 25, wherein the detection probe comprises a molecular beacon or a molecular torch.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method for amplifying a VZV target nucleic acid sequence comprising:
(a) obtaining a sample containing or suspected of containing the VZV target nucleic acid sequence;
(b) contacting the sample with the composition of any one of claims 1-19; and
(c) providing conditions sufficient to amplify the target nucleic acid sequence, thereby producing an amplification product of the VZV target nucleic acid sequence if the VZV target nucleic acid sequence is present in the sample.

### Claim 28 (depends on 20, 21, 22, 23, 24, 25, 26, 27)

The method of claim 27, wherein the method further comprises contacting the sample with the detection probe of any one of claims 20-26 to determine the presence or absence of the amplification product.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method for determine the presence or absence of VZV in a sample comprising:
(a) obtaining a sample containing or suspected of containing a VZV target nucleic acid sequence;
(b) contacting the sample with the composition of any one of claims 1-19;
(c) providing conditions sufficient to amplify the target nucleic acid sequence, thereby producing an amplification product; and
(d) detecting the presence or absence of the amplification product.
